CommentaryThe PRIDE Study and the Conduct of Electroconvulsive Therapy Questions Answered and UnansweredRasmussen, Keith G. MDAuthor Information From the Mayo Clinic Department of Psychiatry and Psychology Rochester, MN. Received for publication January 26, 2017; accepted May 2, 2017. Reprints: Keith G. Rasmussen, MD, Mayo Clinic, Department of Psychiatry and Psychology, Rochester, MN 55905 (e-mail: firstname.lastname@example.org). The author has no conflict of interest or financial disclosures to report. The Journal of ECT: December 2017 - Volume 33 - Issue 4 - p 225-228 doi: 10.1097/YCT.0000000000000430 Buy Metrics Abstract The recently published PRIDE study (prolonging remission in the depressed elderly) constitutes an important contribution to electroconvulsive therapy (ECT) technique, from the standpoint of both the index course to treat depressive symptoms and the post–remission continuation period to prevent relapse. This study was probably the last large, National Institute of Mental Health–funded, multisite ECT technical study for some time to come, so extracting clinically relevant recommendations is worthwhile. In this commentary, the author discusses evidence from this trial relevant to several important clinical index and continuation ECT technical issues and elaborates several unanswered questions deserving further consideration. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.